1
|
Mucci LA, Vinson J, Gold T, Gerke T, Filipenko J, Green RM, Anderson SG, Badal S, Bjartell A, Chi KN, Davis ID, Enting D, Fay AP, Lazarus J, Mateo J, McDermott R, Odedina FT, Olmos D, Omlin A, Popoola AA, Ragin C, Roberts R, Russnes KM, Waihenya C, Stopsack KH, Hyslop T, Villanti P, Kantoff PW, George DJ. IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer. JCO Glob Oncol 2022; 8:e2200154. [PMID: 36332173 PMCID: PMC9668562 DOI: 10.1200/go.22.00154] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
PURPOSE To describe a newly established international registry recruiting diverse patients with advanced prostate cancer across academic and community practices to address unmet needs in this population. PATIENTS AND METHODS Initiated in 2017, IRONMAN (International Registry for Men with Advanced Prostate Cancer) is a prospective cohort of patients with advanced prostate cancer. The study will enroll 5,000 patients with metastatic hormone-sensitive prostate cancer (mHSPC) or castration-resistant prostate cancer (CRPC), recruited from Australia, the Bahamas, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, South Africa, Spain, Sweden, Switzerland, the United Kingdom, and the United States. The study is collecting datatypes to study variation in care and treatment of advanced prostate cancer across countries and across academic, community-based, and government practices with a focus on clinical outcomes, patient-reported outcomes, epidemiologic data, biologic subtypes, and clinician questionnaires. RESULTS Through July 2022, 2,682 eligible patients were enrolled in 11 of 12 active countries. Sixty-six percent of patients have mHSPC, and 34% have CRPC. On the basis of self-report, 11% of patients are Black and 9% are Hispanic. Five Veterans Affairs Medical Centers are enrolling patients. Globally, 23% of patients report being veterans of military service. CONCLUSION To our knowledge, this is the first international cohort of people newly diagnosed with advanced prostate cancer designed to describe variations in patient management, experiences, and outcomes. IRONMAN aims to identify optimal treatment sequences to improve survival, understand patient-reported outcomes, and explore novel biomarkers to understand treatment resistance mechanisms. Insights from IRONMAN will inform and guide future clinical management of people with mHSPC and CRPC. This cohort study will provide real-world evidence to facilitate a better understanding of the survivorship of people with advanced prostate cancer.
Collapse
Affiliation(s)
- Lorelei A. Mucci
- Harvard T.H. Chan School of Public Health, Boston, MA,Lorelei A. Mucci, ScD, Harvard T.H. Chan School of Public Health, 677 Huntington Ave, Room 920, Boston, MA 02115; e-mail:
| | - Jacob Vinson
- Prostate Cancer Clinical Trials Consortium, New York, NY
| | - Theresa Gold
- Prostate Cancer Clinical Trials Consortium, New York, NY
| | - Travis Gerke
- Prostate Cancer Clinical Trials Consortium, New York, NY
| | | | | | - Simon G. Anderson
- The Glasgow-Caribbean Centre for Development Research and the Caribbean Institute of Health Research, The University of the West Indies, Bridgetown, Barbados
| | - Simone Badal
- The University of the West Indies Mona, Kingston, Jamaica
| | | | - Kim N. Chi
- BC Cancer, Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada
| | - Ian D. Davis
- Monash University, Melbourne, Australia,Eastern Health, Melbourne, Australia
| | - Deborah Enting
- Guys St Thomas NHS Foundation Trust, London, United Kingdom
| | - André P. Fay
- Hospital Sao Lucas da PUCRS, Porto Alegre, Brazil
| | - John Lazarus
- University of Cape Town, Cape Town, South Africa
| | - Joaquin Mateo
- Vall d’Hebron Institute of Oncology, Barcelona, Spain
| | - Ray McDermott
- St Vincent's University Hospital & Cancer Trials Ireland, Dublin, Ireland
| | | | - David Olmos
- Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain
| | | | | | | | - Robin Roberts
- UWI School of Clinical Medicine and Research, Nassau, The Bahamas
| | | | | | | | | | | | - Philip W. Kantoff
- Convergent Therapeutics, Cambridge, MA,Memorial Sloan Kettering Cancer Center, New York, NY
| | | | | |
Collapse
|